Adolor — Technical Presentation (February 2006)
17 slides from Adolor's technical presentation, Feb 8, 2006
Slide 1: Adolor Corporation
adolor CORPORATION © 2006 Adolor Corporation. All rights reserved.
Slide 2: Results from Entereg (alvimopan) Phase 3 Clinical Study 14CL314
Results from Entereg® (alvimopan) Phase 3 Clinical Study 14CL314 February 07, 2006
Slide 3: Safe Harbor Statement
Safe Harbor Statement This oral presentation and the questions and answers that follow contain forward-looking statements, including, but not limited to, statements about: our ability to receive FDA approval for our NDA in POI for Entereg® our collaborator’s plans for development of Entereg® in opio
Slide 4: Overview of Study
Overview of Study Entereg® demonstrated a statistically significant difference in the primary endpoint, Time to Recovery of GI Function (GI2) A statistically significant difference in favor of Entereg® was observed in each secondary time to event endpoint, including GI3 and Time to Hospital Discharg
Slide 5: Design
Study 314 Design Double-blind, placebo-controlled, randomized, multi-center 654 patients enrolled in 2 treatment groups (Entereg® 12 mg or placebo) Patients were to receive their first dose 30-90 minutes prior to surgery, and then twice daily until Hospital Discharge or up to 7 days post-surgery
Slide 6: Demographics (MITT)
Study 314 Demographics (MITT) Overall (N=629) 12 mg (N=317) Placebo (N=312) Mean Age (yrs) (Min, Max) 59.8 (19,95) 60.2 (19,91) 59.5 (21,95) Caucasian (%) 265 (85) 264 (83) (84) Female (%) 162 (52) 158 (50) 320 (51) BMI (kg/m2) (Min, Max) 28.6 (16.7, 49.6) 28.0 (13.7, 45.9) 28.4 (13.7, 49.6) Surgery
Slide 7: Statistical Analysis
Study 314 Statistical Analysis Primary Efficacy Endpoint – GI2 Time to recovery of upper AND lower GI Function, measured by the last to occur of: Tolerating solid foods: upper GI Recovery Bowel movement: lower GI Recovery Secondary Time to Event Endpoints Time to GI3 Time to First Bowel Movement Tim
Slide 8: Patient Stratification
Study 314 Patient Stratification Subjects Enrolled (N = 654) Modified Intent-to-Treat (N = 629) Placebo (N =312) Entereg® 12 mg (N = 317) Completed - 305 D/C = 12 AE = 3 Other = 9 Completed - 303 D/C = 9 AE = Other = 7
Slide 9: Results
Study 314 Results Primary Efficacy Endpoint Hazard Ratio P-value Time to GI Recovery (GI2) 1.53 <0.001 Secondary Time to Event Endpoints Time to GI Recovery (GI3) 1.45 <0.001 Time to First Bowel Movement 1.51 <0.001 Time to Ready for Discharge 1.38 <0.001 Time to Discharge Order Written 1.40 <0.001
Slide 10: Entereg Effect on Time to GI Recovery (GI2)
Entereg® Effect on Time to GI Recovery (GI2) Study P-value Hazard Ratio 1.533 <0.001 3021,2 0.029 1.400 3081,2 1.365 0.017 3131,2 <0.001 1.625 0.008 1.299 12 mg dose MITT for bowel resection patients (additional analysis)1. Not primary endpoint2.
Slide 11: Kaplan Meier Curves – GI2
Kaplan Meier Curves – GI2 Time to GI2 Pooled* Studies 302, 308, 313 Time to GI2 Study 314 mg vs. placebo: hazard ratio = 1.53, P<0.001 (Cox Proportional Hazard Model) 12 mg vs. placebo: hazard ratio = 1.46, P<0.001 (Cox Proportional Hazard Model) Placebo 12 mg Placebo 12 mg Mean difference = 18.3 ho
Slide 12: Kaplan Meier Curves – Discharge Order Written
Kaplan Meier Curves – Discharge Order Written Time to DOW Study 314 Time to DOW Pooled* Studies 302, 308, 313 12 mg vs. placebo: hazard ratio = 1.40, P<0.001 (Cox Proportional Hazard Model) 12 mg vs. placebo: hazard ratio = 1.43, P<0.001 (Cox Proportional Hazard Model) Placebo 12 mg Placebo 12 mg Me
Slide 13: Quartile Differences (Placebo - 12mg)
Quartile Differences (Placebo - 12mg) Pooled* Studies 302, 308, 313 Hours 42.0 36.0 30.0 24.0 18.0 12.0 6.0 0.0 25% 50% 75% GI2 DOW Study 314 Hours 42.0 36.0 30.0 24.0 18.0 12.0 6.0 0.0 25% 50% 75% GI2 DOW * Bowel Resections
Slide 14: Responder Analysis - DOW
Study 314 Responder Analysis - DOW Subjects (%) 11+ Placebo 12 mg Mean Placebo 5.8 days Mean 12 mg 5.1 days Postoperative Days
Slide 15: Summary Adverse Event Data
Study 314 Summary Adverse Event Data Placebo 12 mg (N = 325) (N = 329) Nausea 66.2% 57.8% Vomiting 24.6% 14.0% Abdominal Distension 20.3% 17.6%
Slide 16: Anticipated Timeline (as of September 2005)
Anticipated Timeline (as of September 2005) Complete enrollment of study 314 by December 2005 Top-line results targeted for March 2006 Complete response to FDA targeted by June 2006 Complete response triggers 6 month review clock On track On track
Slide 17: Adolor Corporation
adolor CORPORATION Adolor Corporation 700 Pennsylvania Drive Exton, PA 19341 484-595-1500 © 2006 Adolor Corporation. All rights reserved.